Researchers at Sylvester Comprehensive Cancer Center found that the ancient retrovirus HML-2 alters stem cell programming by activating a gene-regulating protein called OCT4, contributing to glioblastoma formation and aggressiveness.
Research by Sylvester Comprehensive Cancer Center reveals African-descent subpopulations worldwide have unique trends in endometrial cancer rates, influenced by diet, stress and socioeconomic factors. The study highlights the importance of focusing on specific regions to assess cancer risks for different population groups.
A retrospective analysis of ambulatory cancer patients found that unmet supportive care needs are associated with increased risk for emergency department visits and hospitalizations. Patients with Black race, Hispanic ethnicity, or low health-related quality-of-life scores were more likely to experience these outcomes.
A study by the Sylvester Comprehensive Cancer Center found significant disparities in federal cancer research funding allocation. Funding for high-incidence cancers among racial and ethnic minorities is often lower than that for similar diseases affecting non-Hispanic white populations.
At ASCO 2023, Sylvester Comprehensive Cancer Center experts are available to discuss a wide range of topics, including Sarcoma research, tumor agnostic precision oncology, and genitourinary cancers. The center's experts also share their perspectives on immunotherapy approaches for prostate cancer, breast cancer treatment, and melanoma.
The ATOM Coalition aims to improve cancer medicine availability and increase the capacity of lower-income countries to diagnose and manage cancer. The coalition prioritizes generic and biosimilar medicines for cancer treatments, targeting countries with high mortality rates.
Dr. Kristin Rojas addresses quality of life concerns for breast cancer patients undergoing endocrine therapy, including sexual health, fertility preservation, and bone health. Her program, Music, has become a model for similar programs across the US, improving patient adherence to treatment.
The Phase 1/2a study found that FORE8394 had low-grade adverse events and was effective against V600 and non-V600 BRAF mutant tumors. The drug targets a previously under-treated population by thwarting cancer cells' ability to escape BRAF inhibition.
A large-scale retrospective analysis by Sylvester Comprehensive Cancer Center researchers found that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestries. Men of African ancestry are less likely to receive comprehensive genetic profiling and tar...
A study published in Science Translational Medicine has identified immature Natural Killer (NK) cells as a key factor in promoting disease progression in triple-negative breast cancer. The researchers suggest that targeting these rogue NK cells could lead to new and more effective treatments for this aggressive form of breast cancer.
Researchers at Sylvester Comprehensive Cancer Center found that mesothelioma patients with timely treatment and access to specialized care have better outcomes. However, disparities in access to care are evident, with Black patients being 80% more likely to die than white patients.
Sylvester researchers have identified a signaling circuit that instigates immunosuppression and tumor-promoting inflammation in the pancreatic tumor microenvironment, driving treatment resistance. Immature neutrophils are found to play a critical role in this process.
A new study using whole genome sequencing identifies previously unknown mutations driving Hodgkin lymphoma development. The research provides temporal insights into tumor evolution, enabling more precise targeted treatment options.
Researchers have developed a sophisticated AI algorithm, SPHINKS, that can refine omics datasets and pinpoint protein kinases responsible for tumor growth in glioblastoma. The algorithm has the potential to provide personalized treatments for patients with aggressive brain cancer.
The COVID-19 Prevention Network's coordinated approach to Phase 3 clinical trials has yielded a comprehensive database of trial participants' data. This dataset will help researchers address pressing questions about SARS-CoV-2 and inform future vaccine development.
People living with HIV are at high risk of tuberculosis infection and disease, yet many questions remain unanswered about developing an effective TB vaccine. The NIH/DAIDS Cross-Network calls for their inclusion in clinical trials to prioritize access to safe and effective TB vaccines.
A newly defined biomarker called PT80 appears effective as a surrogate endpoint to predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. PT80 predicts the 80% neutralizing antibody titer of a bnAb recipient's blood sample at a given time to a given virus.
The HIV Vaccine Trials Network is launching a new registry to connect people interested in supporting HIV vaccine research with clinical trials in their communities. The 'Help End HIV' campaign aims to raise awareness about the urgent need for HIV clinical trial volunteers, particularly among young people.
The authors advocate for integrated programs to diagnose, vaccinate, and manage HIV and COVID-19 patients, building on successful donor initiatives like PEPFAR and GFATM. This approach is crucial to address the intersecting pandemics and their detrimental effects on global health.
A new Phase 1 clinical trial has enrolled its first 12 participants, evaluating the safety and immune responses of three experimental HIV vaccines using mRNA technology. The study aims to understand how the immune system responds to these vaccines and gain insights into developing an HIV vaccine regimen.
The Ubuntu study evaluates the efficacy of Moderna mRNA-1273 against the omicron variant and identifies optimal dosages for people living with HIV. The trial, conducted in eight sub-Saharan countries, aims to inform vaccine strategies for this high-risk population.
A recent study published in PLOS ONE demonstrates the critical role of community engagement in increasing diverse participation in vaccine clinical trials. The research found that robust engagement strategies can overcome barriers to inclusion, particularly among Black, Indigenous, and people of color communities.
The Alzheimer's Drug Discovery Foundation has provided NeuroVision Imaging Inc. with additional funding to accelerate the development of a novel blood-based lab test that can predict dementia before clinical onset. This technology has the potential to make diagnostic testing more practical, less invasive and less costly.
The Prevent COVID U study has expanded to enroll young adults ages 18-29, including those who choose not to receive a vaccine. The trial aims to test the effectiveness of the Moderna COVID-19 Vaccine in preventing infection and transmission of SARS-CoV-2.
The AMP trials tested a broadly neutralizing antibody called VRC01, which was effective at preventing the acquisition of HIV strains in sensitive populations. However, results showed that more than one single bnAb is needed to prevent HIV acquisition, highlighting the need for combination monoclonal antibody cocktails.
NeuroVision Imaging, Inc. has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to develop reliable and affordable biomarker tests for Alzheimer's disease and related dementias. The goal is to improve clinical trials and monitor response to treatments.
Researchers at Cedars-Sinai and NeuroVision LLC have developed an experimental optical imaging system that detects retinal beta-amyloid, a hallmark of Alzheimer's disease. The study found a 4.7-fold increase in retinal plaque burden in patients with Alzheimer's compared to controls.
NeuroVision is participating in a landmark A4 study to test a new investigational treatment that may reduce beta-amyloid accumulation in the brain. The substudy will use NeuroVision's retinal imaging technology to characterize amyloid imaging findings and assess longitudinal changes.
A RAND/Harvard study found that teledermatology improved access to dermatologists for Medicaid patients, with half of those receiving any dermatology care using the service. The collaboration between Direct Dermatology and Health Plan of San Joaquin achieved significant increases in patient visits with dermatologists.
Researchers have identified a small RNA molecule, SNORA42, that enables aggressive colorectal cancers to progress and resist treatment. Detecting high levels of this biomarker in patient tissues may help clinicians determine which patients benefit from more aggressive therapy.